GlaxoSmithKline Biologicals SA v. Human Biolife India Pvt. Ltd. & Ors.
A settlement in a pharmaceutical trademark dispute can include cessation of confusingly similar marks, withdrawal of applications and removal of infringing online listings.
Short Description About the Case
This commercial trademark dispute concerned the use of marks allegedly similar to established vaccine brands owned by GlaxoSmithKline Biologicals SA. The case ended through a settlement recorded by the Delhi High Court.
Facts
GlaxoSmithKline Biologicals SA brought proceedings against Human Biolife India Pvt. Ltd. and other defendants in relation to pharmaceutical marks associated with its vaccine brands, including ENGERIX, HAVRIX, INFANRIX, ROTARIX, CERVARIX and SYNFLORIX. The plaintiff alleged that the defendants had adopted marks such as RUTORIX, DROTARIX, AMIRIX, CEFTARIX and MIRIX for pharmaceutical products, creating a risk of confusion with its established marks.
The parties entered into a settlement agreement dated 24 April 2026, which was subsequently placed before the Court.
Findings
The matter was resolved on the basis of the settlement. The recorded terms required the defendant to stop the infringing use, take steps to recall the relevant products, cancel the relevant trademark applications and remove online listings identified in the settlement. The case therefore demonstrates how a negotiated resolution can address not only use of the mark but also related product distribution and online promotion.
Since the decree was based on the parties’ settlement, it should not be described as a fully contested judicial finding that every disputed mark was confusingly similar after trial.
Suggestion
Pharmaceutical businesses should conduct careful clearance searches before selecting a product name, particularly where the proposed mark shares prominent endings, syllables or structure with established medicine or vaccine brands. Trademark owners should preserve evidence of product packaging, distribution, online listings and relevant applications. Settlement terms should clearly cover discontinued use, product recall, cancellation of applications and removal of digital listings where those steps are agreed.
Judgment / Principle
The Delhi High Court decreed the suit in terms of the settlement. The recorded relief included cessation of the disputed use, recall-related obligations, cancellation of trademark applications and removal of specified online listings. The practical lesson is to ensure that settlement terms address all channels through which a potentially infringing pharmaceutical mark is being used.



